Label: SYNTHROID- levothyroxine sodium tablet

  • NDC Code(s): 0074-3727-13, 0074-3727-19, 0074-3727-71, 0074-3727-72, view more
    0074-3727-90, 0074-4341-13, 0074-4341-19, 0074-4341-72, 0074-4341-90, 0074-4552-11, 0074-4552-13, 0074-4552-19, 0074-4552-71, 0074-4552-72, 0074-4552-90, 0074-5182-11, 0074-5182-13, 0074-5182-19, 0074-5182-71, 0074-5182-72, 0074-5182-90, 0074-6594-13, 0074-6594-19, 0074-6594-71, 0074-6594-72, 0074-6594-90, 0074-6624-11, 0074-6624-13, 0074-6624-19, 0074-6624-71, 0074-6624-72, 0074-6624-90, 0074-7068-11, 0074-7068-13, 0074-7068-19, 0074-7068-71, 0074-7068-72, 0074-7068-90, 0074-7069-11, 0074-7069-19, 0074-7069-71, 0074-7069-72, 0074-7069-90, 0074-7070-13, 0074-7070-19, 0074-7070-71, 0074-7070-72, 0074-7070-90, 0074-7148-11, 0074-7148-19, 0074-7148-71, 0074-7148-72, 0074-7148-90, 0074-7149-19, 0074-7149-90, 0074-9296-13, 0074-9296-19, 0074-9296-71, 0074-9296-72, 0074-9296-90
  • Packager: AbbVie Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: New Drug Application

Drug Label Information

Updated March 2, 2017

If you are a consumer or patient please visit this version.

  • BOXED WARNING(What is this?)

    WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

    • Thyroid hormones, including SYNTHROID, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss.
    • In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction.
    • Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)].
    Close
  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use SYNTHROID® safely and effectively. See full prescribing information for SYNTHROID.
    SYNTHROID® (levothyroxine sodium) tablets, for oral use
    Initial U.S. Approval: 2002

    WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

    See full prescribing information for complete boxed warning

    • Thyroid hormones, including SYNTHROID should not be used for the treatment of obesity or for weight loss.
    • Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity (6, 10).

    INDICATIONS AND USAGE

    SYNTHROID is levothyroxine sodium (T4) indicated for:

    • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. (1)
    • Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. (1)

    Limitations of Use:

    • - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients.
    • - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

    DOSAGE AND ADMINISTRATION

    • Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. (2.1)
    • Administer at least 4 hours before or after drugs that are known to interfere with absorption. (2.1)
    • Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (2.1)
    • Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, and concomitant medications. Peak therapeutic effect may not be attained for 4-6 weeks. (2.2)
    • See full prescribing information for dosing in specific patient populations. (2.3)
    • Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (2.4)

    DOSAGE FORMS AND STRENGTHS

    Tablets:  25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200, and 300 mcg (3)

    CONTRAINDICATIONS

    • Uncorrected adrenal insufficiency. (4)

    WARNINGS AND PRECAUTIONS

    • Cardiac adverse reactions in the elderly and in patients with underlying cardiovascular disease: Initiate SYNTHROID at less than the full replacement dose because of the increased risk of cardiac adverse reactions, including atrial fibrillation. (2.3, 5.1, 8.5)
    • Myxedema coma: Do not use oral thyroid hormone drug products to treat myxedema coma. (5.2)
    • Acute adrenal crisis in patients with concomitant adrenal insufficiency: Treat with replacement glucocorticoids prior to initiation of SYNTHROID treatment. (5.3)
    • Prevention of hyperthyroidism or incomplete treatment of hypothyroidism: Proper dose titration and careful monitoring is critical to prevent the persistence of hypothyroidism or the development of hyperthyroidism. (5.4)
    • Worsening of diabetic control: Therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing thyroid hormone therapy. (5.5)
    • Decreased bone mineral density associated with thyroid hormone over-replacement: Over-replacement can increase bone resorption and decrease bone mineral density. Give the lowest effective dose. (5.6)

    ADVERSE REACTIONS

    Adverse reactions associated with SYNTHROID therapy are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash. (6)

    To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    DRUG INTERACTIONS

    See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to SYNTHROID. (7)

    USE IN SPECIFIC POPULATIONS

    Pregnancy may require the use of higher doses of SYNTHROID. (2.3, 8.1)

    See 17 for PATIENT COUNSELING INFORMATION.

    Revised: 2/2017

    Close
  • FULL PRESCRIBING INFORMATION: CONTENTS*

    WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS

    1 INDICATIONS AND USAGE

    2 DOSAGE AND ADMINISTRATION

    2.1 General Administration Information

    2.2 General Principles of Dosing

    2.3 Dosing in Specific Patient Populations

    2.4 Monitoring TSH and/or Thyroxine (T4) Levels

    3 DOSAGE FORMS AND STRENGTHS

    4 CONTRAINDICATIONS

    5 WARNINGS AND PRECAUTIONS

    5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease

    5.2 Myxedema Coma

    5.3 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency

    5.4 Prevention of Hyperthyroidism or Incomplete Treatment of Hypothyroidism

    5.5 Worsening of Diabetic Control

    5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

    6 ADVERSE REACTIONS

    Adverse Reactions in Children

    Hypersensitivity Reactions

    7 DRUG INTERACTIONS

    7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics

    7.2 Antidiabetic Therapy

    7.3 Oral Anticoagulants

    7.4 Digitalis Glycosides

    7.5 Antidepressant Therapy

    7.6 Ketamine

    7.7 Sympathomimetics

    7.8 Tyrosine-Kinase Inhibitors

    7.9 Drug-Food Interactions

    7.10 Drug-Laboratory Test Interactions

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    8.2 Lactation

    8.5 Geriatric Use

    10 OVERDOSAGE

    11 DESCRIPTION

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    12.2 Pharmacodynamics

    12.3 Pharmacokinetics

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    16 HOW SUPPLIED/STORAGE AND HANDLING

    Storage Conditions

    17 PATIENT COUNSELING INFORMATION

    *
    Sections or subsections omitted from the full prescribing information are not listed.
    Close
  • 1 INDICATIONS AND USAGE

    Hypothyroidism

    SYNTHROID is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.

    Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression

    SYNTHROID is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

    • Limitations of Use:
    • SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism [see Warnings and Precautions(5.4)].
    • SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
    Close
  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Administration Information

    Administer SYNTHROID as a single daily dose, on an empty stomach, one-half to one hour before breakfast.

    Administer SYNTHROID at least 4 hours before or after drugs known to interfere with SYNTHROID absorption [see Drug Interactions (7.1)].

    Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect SYNTHROID absorption [see Drug Interactions (7.9) and Clinical Pharmacology (12.3)].

    Administer SYNTHROID to infants and children who cannot swallow intact tablets by crushing the tablet, suspending the freshly crushed tablet in a small amount (5 to 10 mL or 1 to 2 teaspoons) of water and immediately administering the suspension by spoon or dropper. Do not store the suspension. Do not administer in foods that decrease absorption of SYNTHROID, such as soybean-based infant formula [see Drug Interactions (7.9)].

    2.2 General Principles of Dosing

    The dose of SYNTHROID for hypothyroidism or pituitary TSH suppression depends on a variety of factors including: the patient's age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food and the specific nature of the condition being treated [see Dosage and Administration (2.3), Warnings and Precautions (5), and Drug Interactions (7)]. Dosing must be individualized to account for these factors and dose adjustments made based on periodic assessment of the patient's clinical response and laboratory parameters [see Dosage and Administration (2.4)].

    The peak therapeutic effect of a given dose of SYNTHROID may not be attained for 4 to 6 weeks.

    2.3 Dosing in Specific Patient Populations

    Primary Hypothyroidism in Adults and in Adolescents in Whom Growth and Puberty are Complete

    Start SYNTHROID at the full replacement dose in otherwise healthy, non-elderly individuals who have been hypothyroid for only a short time (such as a few months). The average full replacement dose of SYNTHROID is approximately 1.6 mcg per kg per day (for example: 100 to 125 mcg per day for a 70 kg adult).

    Adjust the dose by 12.5 to 25 mcg increments every 4 to 6 weeks until the patient is clinically euthyroid and the serum TSH returns to normal. Doses greater than 200 mcg per day are seldom required. An inadequate response to daily doses of greater than 300 mcg per day is rare and may indicate poor compliance, malabsorption, drug interactions, or a combination of these factors.

    For elderly patients or patients with underlying cardiac disease, start with a dose of 12.5 to 25 mcg per day. Increase the dose every 6 to 8 weeks, as needed until the patient is clinically euthyroid and the serum TSH returns to normal. The full replacement dose of SYNTHROID may be less than 1 mcg per kg per day in elderly patients.

    In patients with severe longstanding hypothyroidism, start with a dose of 12.5 to 25 mcg per day. Adjust the dose in 12.5 to 25 mcg increments every 2 to 4 weeks until the patient is clinically euthyroid and the serum TSH level is normalized.

    Secondary or Tertiary Hypothyroidism

    Start SYNTHROID at the full replacement dose in otherwise healthy, non-elderly individuals. Start with a lower dose in elderly patients, patients with underlying cardiovascular disease or patients with severe longstanding hypothyroidism as described above. Serum TSH is not a reliable measure of SYNTHROID dose adequacy in patients with secondary or tertiary hypothyroidism and should not be used to monitor therapy. Use the serum free-T4 level to monitor adequacy of therapy in this patient population. Titrate SYNTHROID dosing per above instructions until the patient is clinically euthyroid and the serum free-T4 level is restored to the upper half of the normal range.

    Pediatric Dosage - Congenital or Acquired Hypothyroidism

    The recommended daily dose of SYNTHROID in pediatric patients with hypothyroidism is based on body weight and changes with age as described in Table 1. Start SYNTHROID at the full daily dose in most pediatric patients. Start at a lower starting dose in newborns (0-3 months) at risk for cardiac failure and in children at risk for hyperactivity (see below). Monitor for clinical and laboratory response [see Dosage and Administration (2.4)].

    Table 1. SYNTHROID Dosing Guidelines for Pediatric Hypothyroidism
    AGE Daily Dose Per Kg Body Weighta
    0-3 months 10-15 mcg/kg/day
    3-6 months 8-10 mcg/kg/day
    6-12 months 6-8 mcg/kg/day
    1-5 years 5-6 mcg/kg/day
    6-12 years 4-5 mcg/kg/day
    Greater than 12 years but growth and puberty incomplete 2-3 mcg/kg/day
    Growth and puberty complete 1.6 mcg/kg/day
    1. The dose should be adjusted based on clinical response and laboratory parameters [see Dosage and Administration (2.4) and Use in Specific Populations (8.4)].

    Newborns (0-3 months) at risk for cardiac failure: Consider a lower starting dose in newborns at risk for cardiac failure.

    Increase the dose every 4 to 6 weeks as needed based on clinical and laboratory response.

    Children at risk for hyperactivity: To minimize the risk of hyperactivity in children, start at one-fourth the recommended full replacement dose, and increase on a weekly basis by one-fourth the full recommended replacement dose until the full recommended replacement dose is reached.

    Pregnancy

    Pre-existing Hypothyroidism: SYNTHROID dose requirements may increase during pregnancy. Measure serum TSH and free-T4 as soon as pregnancy is confirmed and, at minimum, during each trimester of pregnancy. In patients with primary hypothyroidism, maintain serum TSH in the trimester-specific reference range. For patients with serum TSH above the normal trimester-specific range, increase the dose of SYNTHROID by 12.5 to 25 mcg/day and measure TSH every 4 weeks until a stable SYNTHROID dose is reached and serum TSH is within the normal trimester-specific range. Reduce SYNTHROID dosage to pre-pregnancy levels immediately after delivery and measure serum TSH levels 4 to 8 weeks postpartum to ensure SYNTHROID dose is appropriate.

    New Onset Hypothyroidism: Normalize thyroid function as rapidly as possible. In patients with moderate to severe signs and symptoms of hypothyroidism, start SYNTHROID at the full replacement dose (1.6 mcg per kg body weight per day). In patients with mild hypothyroidism (TSH < 10 IU per liter) start SYNTHROID at 1.0 mcg per kg body weight per day. Evaluate serum TSH every 4 weeks and adjust SYNTHROID dosage until a serum TSH is within the normal trimester specific range [see Use in Specific Populations (8.1)].

    TSH Suppression in Well-differentiated Thyroid Cancer

    Generally, TSH is suppressed to below 0.1 IU per liter, and this usually requires a SYNTHROID dose of greater than 2 mcg per kg per day. However, in patients with high-risk tumors, the target level for TSH suppression may be lower.

    2.4 Monitoring TSH and/or Thyroxine (T4) Levels

    Assess the adequacy of therapy by periodic assessment of laboratory tests and clinical evaluation. Persistent clinical and laboratory evidence of hypothyroidism despite an apparent adequate replacement dose of SYNTHROID may be evidence of inadequate absorption, poor compliance, drug interactions, or a combination of these factors.

    Adults

    In adult patients with primary hypothyroidism, monitor serum TSH levels after an interval of 6 to 8 weeks after any change in dose. In patients on a stable and appropriate replacement dose, evaluate clinical and biochemical response every 6 to 12 months and whenever there is a change in the patient’s clinical status.

    Pediatrics

    In patients with congenital hypothyroidism, assess the adequacy of replacement therapy by measuring both serum TSH and total or free-T4. Monitor TSH and total or free-T4 in children as follows: 2 and 4 weeks after the initiation of treatment, 2 weeks after any change in dosage, and then every 3 to 12 months thereafter following dose stabilization until growth is completed. Poor compliance or abnormal values may necessitate more frequent monitoring. Perform routine clinical examination, including assessment of development, mental and physical growth, and bone maturation, at regular intervals.

    While the general aim of therapy is to normalize the serum TSH level, TSH may not normalize in some patients due to in utero hypothyroidism causing a resetting of pituitary-thyroid feedback. Failure of the serum T4 to increase into the upper half of the normal range within 2 weeks of initiation of SYNTHROID therapy and/or of the serum TSH to decrease below 20 IU per liter within 4 weeks may indicate the child is not receiving adequate therapy. Assess compliance, dose of medication administered, and method of administration prior to increasing the dose of SYNTHROID [see Warnings and Precautions (5.1) and Use in Specific Populations (8.4)].

    Secondary and Tertiary Hypothyroidism

    Monitor serum free-T4 levels and maintain in the upper half of the normal range in these patients.

    Close
  • 3 DOSAGE FORMS AND STRENGTHS

    SYNTHROID tablets are available as follows:

    Tablet Strength Tablet Color/Shape Tablet Markings
    25 mcg Orange/Round “SYNTHROID” and “25”
    50 mcg White/Round “SYNTHROID” and “50”
    75 mcg Violet/Round “SYNTHROID” and “75”
    88 mcg Olive/Round “SYNTHROID” and “88”
    100 mcg Yellow/Round “SYNTHROID” and “100”
    112 mcg Rose/Round “SYNTHROID” and “112”
    125 mcg Brown/Round “SYNTHROID” and “125”
    137 mcg Turquoise/Round “SYNTHROID” and “137”
    150 mcg Blue/Round “SYNTHROID” and “150”
    175 mcg Lilac/Round “SYNTHROID” and “175”
    200 mcg Pink/Round “SYNTHROID” and “200”
    300 mcg Green/Round “SYNTHROID” and “300”
    Close
  • 4 CONTRAINDICATIONS

    SYNTHROID is contraindicated in patients with uncorrected adrenal insufficiency [see Warnings and Precautions (5.3)].

    Close
  • 5 WARNINGS AND PRECAUTIONS

    5.1 Cardiac Adverse Reactions in the Elderly and in Patients with Underlying Cardiovascular Disease

    Over-treatment with levothyroxine may cause an increase in heart rate, cardiac wall thickness, and cardiac contractility and may precipitate angina or arrhythmias, particularly in patients with cardiovascular disease and in elderly patients. Initiate SYNTHROID therapy in this population at lower doses than those recommended in younger individuals or in patients without cardiac disease [see Dosage and Administration (2.3), Use in Specific Populations (8.5)].

    Monitor for cardiac arrhythmias during surgical procedures in patients with coronary artery disease receiving suppressive SYNTHROID therapy. Monitor patients receiving concomitant SYNTHROID and sympathomimetic agents for signs and symptoms of coronary insufficiency.

    If cardiac symptoms develop or worsen, reduce the SYNTHROID dose or withhold for one week and restart at a lower dose.

    5.2 Myxedema Coma

    Myxedema coma is a life-threatening emergency characterized by poor circulation and hypometabolism, and may result in unpredictable absorption of levothyroxine sodium from the gastrointestinal tract. Use of oral thyroid hormone drug products is not recommended to treat myxedema coma. Administer thyroid hormone products formulated for intravenous administration to treat myxedema coma.

    5.3 Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency

    Thyroid hormone increases metabolic clearance of glucocorticoids. Initiation of thyroid hormone therapy prior to initiating glucocorticoid therapy may precipitate an acute adrenal crisis in patients with adrenal insufficiency. Treat patients with adrenal insufficiency with replacement glucocorticoids prior to initiating treatment with SYNTHROID [see Contraindications (4)].

    5.4 Prevention of Hyperthyroidism or Incomplete Treatment of Hypothyroidism

    SYNTHROID has a narrow therapeutic index. Over- or undertreatment with SYNTHROID may have negative effects on growth and development, cardiovascular function, bone metabolism, reproductive function, cognitive function, emotional state, gastrointestinal function, and glucose and lipid metabolism. Titrate the dose of SYNTHROID carefully and monitor response to titration to avoid these effects [see Dosage and Administration (2.4)]. Monitor for the presence of drug or food interactions when using SYNTHROID and adjust the dose as necessary [see Drug Interactions (7.9) and Clinical Pharmacology (12.3)].

    5.5 Worsening of Diabetic Control

    Addition of levothyroxine therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control after starting, changing, or discontinuing SYNTHROID [see Drug Interactions (7.2)].

    5.6 Decreased Bone Mineral Density Associated with Thyroid Hormone Over-Replacement

    Increased bone resorption and decreased bone mineral density may occur as a result of levothyroxine over-replacement, particularly in post-menopausal women. The increased bone resorption may be associated with increased serum levels and urinary excretion of calcium and phosphorous, elevations in bone alkaline phosphatase, and suppressed serum parathyroid hormone levels. Administer the minimum dose of SYNTHROID that achieves the desired clinical and biochemical response to mitigate this risk.

    Close
  • 6 ADVERSE REACTIONS

    Adverse reactions associated with SYNTHROID therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5), Overdosage (10)]. They include the following:

    • General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating
    • Central nervous system: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia
    • Musculoskeletal: tremors, muscle weakness, muscle spasm
    • Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest
    • Respiratory: dyspnea
    • Gastrointestinal: diarrhea, vomiting, abdominal cramps, elevations in liver function tests
    • Dermatologic: hair loss, flushing, rash
    • Endocrine: decreased bone mineral density
    • Reproductive: menstrual irregularities, impaired fertility

    Seizures have been reported rarely with the institution of levothyroxine therapy.

    Adverse Reactions in Children

    Pseudotumor cerebri and slipped capital femoral epiphysis have been reported in children receiving levothyroxine therapy. Overtreatment may result in craniosynostosis in infants and premature closure of the epiphyses in children with resultant compromised adult height.

    Hypersensitivity Reactions

    Hypersensitivity reactions to inactive ingredients have occurred in patients treated with thyroid hormone products. These include urticaria, pruritus, skin rash, flushing, angioedema, various gastrointestinal symptoms (abdominal pain, nausea, vomiting and diarrhea), fever, arthralgia, serum sickness, and wheezing. Hypersensitivity to levothyroxine itself is not known to occur.

    Close
  • 7 DRUG INTERACTIONS

    7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics

    Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to SYNTHROID (see Tables 2-5 below).

    Table 2. Drugs That May Decrease T4 Absorption (Hypothyroidism)
    Potential impact: Concurrent use may reduce the efficacy of SYNTHROID by binding and delaying or preventing absorption, potentially resulting in hypothyroidism.
    Drug or Drug Class Effect
    Calcium Carbonate
    Ferrous Sulfate
    Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. Administer SYNTHROID at least 4 hours apart from these agents.
    Orlistat Monitor patients treated concomitantly with orlistat and SYNTHROID for changes in thyroid function.
    Bile Acid Sequestrants
    - Colesevelam
    - Cholestyramine
    - Colestipol
    Ion Exchange Resins
    - Kayexalate
    - Sevelamer
    Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer SYNTHROID at least 4 hours prior to these drugs or monitor TSH levels.
    Other drugs:
    Proton Pump Inhibitors
    Sucralfate
    Antacids
    - Aluminum & Magnesium Hydroxides
    - Simethicone
    Gastric acidity is an essential requirement for adequate absorption of levothyroxine. Sucralfate, antacids and proton pump inhibitors may cause hypochlorhydria, affect intragastric pH, and reduce levothyroxine absorption. Monitor patients appropriately.


    Table 3. Drugs That May Alter T4 and Triiodothyronine (T3) Serum Transport Without Affecting Free Thyroxine (FT4) Concentration (Euthyroidism)
    Drug or Drug Class Effect
    Clofibrate
    Estrogen-containing oral contraceptives
    Estrogens (oral)
    Heroin / Methadone
    5-Fluorouracil
    Mitotane
    Tamoxifen
    These drugs may increase serum thyroxine-binding globulin (TBG) concentration.
    Androgens / Anabolic Steroids
    Asparaginase
    Glucocorticoids
    Slow-Release Nicotinic Acid
    These drugs may decrease serum TBG concentration.
    Potential impact (below): Administration of these agents with SYNTHROID results in an initial transient increase in FT4. Continued administration results in a decrease in serum T4 and normal FT4 and TSH concentrations.
    Salicylates (> 2 g/day) Salicylates inhibit binding of T4 and T3 to TBG and transthyretin. An initial increase in serum FT4 is followed by return of FT4 to normal levels with sustained therapeutic serum salicylate concentrations, although total T4 levels may decrease by as much as 30%.
    Other drugs:
    Carbamazepine
    Furosemide (> 80 mg IV)
    Heparin
    Hydantoins
    Non-Steroidal Anti-inflammatory Drugs
    - Fenamates
    These drugs may cause protein-binding site displacement. Furosemide has been shown to inhibit the protein binding of T4 to TBG and albumin, causing an increase free T4 fraction in serum. Furosemide competes for T4-binding sites on TBG, prealbumin, and albumin, so that a single high dose can acutely lower the total T4 level. Phenytoin and carbamazepine reduce serum protein binding of levothyroxine, and total and free T4 may be reduced by 20% to 40%, but most patients have normal serum TSH levels and are clinically euthyroid. Closely monitor thyroid hormone parameters.


    Table 4. Drugs That May Alter Hepatic Metabolism of T4 (Hypothyroidism)
    Potential impact: Stimulation of hepatic microsomal drug-metabolizing enzyme activity may cause increased hepatic degradation of levothyroxine, resulting in increased SYNTHROID requirements.
    Drug or Drug Class Effect
    Phenobarbital
    Rifampin
    Phenobarbital has been shown to reduce the response to thyroxine. Phenobarbital increases L-thyroxine metabolism by inducing uridine 5’-diphospho-glucuronosyltransferase (UGT) and leads to a lower T4 serum levels. Changes in thyroid status may occur if barbiturates are added or withdrawn from patients being treated for hypothyroidism. Rifampin has been shown to accelerate the metabolism of levothyroxine.


    Table 5. Drugs That May Decrease Conversion of T4 to T3
    Potential impact: Administration of these enzyme inhibitors decreases the peripheral conversion of T4 to T3, leading to decreased T3 levels. However, serum T4 levels are usually normal but may occasionally be slightly increased.
    Drug or Drug Class Effect
    Beta-adrenergic antagonists
    (e.g., Propranolol > 160 mg/day)
    In patients treated with large doses of propranolol (> 160 mg/day), T3 and T4 levels change, TSH levels remain normal, and patients are clinically euthyroid. Actions of particular beta-adrenergic antagonists may be impaired when a hypothyroid patient is converted to the euthyroid state.
    Glucocorticoids
    (e.g., Dexamethasone > 4 mg/day)
    Short-term administration of large doses of glucocorticoids may decrease serum T3 concentrations by 30% with minimal change in serum T4 levels. However, long-term glucocorticoid therapy may result in slightly decreased T3 and T4 levels due to decreased TBG production (See above).
    Other drugs:
    Amiodarone
    Amiodarone inhibits peripheral conversion of levothyroxine (T4) to triiodothyronine (T3) and may cause isolated biochemical changes (increase in serum free-T4, and decreased or normal free-T3) in clinically euthyroid patients.

    7.2 Antidiabetic Therapy

    Addition of SYNTHROID therapy in patients with diabetes mellitus may worsen glycemic control and result in increased antidiabetic agent or insulin requirements. Carefully monitor glycemic control, especially when thyroid therapy is started, changed, or discontinued [see Warnings and Precautions (5.5)].

    7.3 Oral Anticoagulants

    SYNTHROID increases the response to oral anticoagulant therapy. Therefore, a decrease in the dose of anticoagulant may be warranted with correction of the hypothyroid state or when the SYNTHROID dose is increased. Closely monitor coagulation tests to permit appropriate and timely dosage adjustments.

    7.4 Digitalis Glycosides

    SYNTHROID may reduce the therapeutic effects of digitalis glycosides. Serum digitalis glycoside levels may decrease when a hypothyroid patient becomes euthyroid, necessitating an increase in the dose of digitalis glycosides.

    7.5 Antidepressant Therapy

    Concurrent use of tricyclic (e.g., amitriptyline) or tetracyclic (e.g., maprotiline) antidepressants and SYNTHROID may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines. Toxic effects may include increased risk of cardiac arrhythmias and central nervous system stimulation. SYNTHROID may accelerate the onset of action of tricyclics. Administration of sertraline in patients stabilized on SYNTHROID may result in increased SYNTHROID requirements.

    7.6 Ketamine

    Concurrent use of ketamine and SYNTHROID may produce marked hypertension and tachycardia. Closely monitor blood pressure and heart rate in these patients.

    7.7 Sympathomimetics

    Concurrent use of sympathomimetics and SYNTHROID may increase the effects of sympathomimetics or thyroid hormone. Thyroid hormones may increase the risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease.

    7.8 Tyrosine-Kinase Inhibitors

    Concurrent use of tyrosine-kinase inhibitors such as imatinib may cause hypothyroidism. Closely monitor TSH levels in such patients.

    7.9 Drug-Food Interactions

    Consumption of certain foods may affect SYNTHROID absorption thereby necessitating adjustments in dosing [see Dosage and Administration (2.1)]. Soybean flour, cottonseed meal, walnuts, and dietary fiber may bind and decrease the absorption of SYNTHROID from the gastrointestinal tract. Grapefruit juice may delay the absorption of levothyroxine and reduce its bioavailability.

    7.10 Drug-Laboratory Test Interactions

    Consider changes in TBG concentration when interpreting T4 and T3 values. Measure and evaluate unbound (free) hormone and/or determine the free-T4 index (FT4I) in this circumstance. Pregnancy, infectious hepatitis, estrogens, estrogen-containing oral contraceptives, and acute intermittent porphyria increase TBG concentration. Nephrosis, severe hypoproteinemia, severe liver disease, acromegaly, androgens, and corticosteroids decrease TBG concentration. Familial hyper- or hypo-thyroxine binding globulinemias have been described, with the incidence of TBG deficiency approximating 1 in 9000.

    Close
  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Experience with levothyroxine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages [see Data]. There are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. Since TSH levels may increase during pregnancy, TSH should be monitored and SYNTHROID dosage adjusted during pregnancy [see Clinical Considerations]. There are no animal studies conducted with levothyroxine during pregnancy. SYNTHROID should not be discontinued during pregnancy and hypothyroidism diagnosed during pregnancy should be promptly treated.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

    Clinical Considerations

    Disease-Associated Maternal and/or Embryo/Fetal Risk

    Maternal hypothyroidism during pregnancy is associated with a higher rate of complications, including spontaneous abortion, gestational hypertension, pre‑eclampsia, stillbirth, and premature delivery. Untreated maternal hypothyroidism may have an adverse effect on fetal neurocognitive development.

    Dose Adjustments During Pregnancy and the Postpartum Period

    Pregnancy may increase SYNTHROID requirements. Serum TSH levels should be monitored and the SYNTHROID dosage adjusted during pregnancy. Since postpartum TSH levels are similar to preconception values, the SYNTHROID dosage should return to the pre-pregnancy dose immediately after delivery [see Dosage and Administration (2.3)].

    Data

    Human Data

    Levothyroxine is approved for use as a replacement therapy for hypothyroidism. There is a long experience of levothyroxine use in pregnant women, including data from post-marketing studies that have not reported increased rates of fetal malformations, miscarriages or other adverse maternal or fetal outcomes associated with levothyroxine use in pregnant women.

    8.2 Lactation

    Risk Summary

    Limited published studies report that levothyroxine is present in human milk. However, there is insufficient information to determine the effects of levothyroxine on the breastfed infant and no available information on the effects of levothyroxine on milk production. Adequate levothyroxine treatment during lactation may normalize milk production in hypothyroid lactating mothers. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for SYNTHROID and any potential adverse effects on the breastfed infant from SYNTHROID or from the underlying maternal condition.

    8.4 Pediatric Use

    The initial dose of SYNTHROID varies with age and body weight. Dosing adjustments are based on an assessment of the individual patient's clinical and laboratory parameters [see Dosage and Administration (2.3, 2.4)].

    In children in whom a diagnosis of permanent hypothyroidism has not been established, discontinue SYNTHROID administration for a trial period, but only after the child is at least 3 years of age. Obtain serum T4 and TSH levels at the end of the trial period, and use laboratory test results and clinical assessment to guide diagnosis and treatment, if warranted.

    Congenital Hypothyroidism[See Dosage and Administration (2.3, 2.4)]

    Rapid restoration of normal serum T4 concentrations is essential for preventing the adverse effects of congenital hypothyroidism on intellectual development as well as on overall physical growth and maturation. Therefore, initiate SYNTHROID therapy immediately upon diagnosis. Levothyroxine is generally continued for life in these patients.

    Closely monitor infants during the first 2 weeks of SYNTHROID therapy for cardiac overload, arrhythmias, and aspiration from avid suckling.

    Closely monitor patients to avoid undertreatment or overtreatment. Undertreatment may have deleterious effects on intellectual development and linear growth. Overtreatment is associated with craniosynostosis in infants, may adversely affect the tempo of brain maturation, and may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.

    Acquired Hypothyroidism in Pediatric Patients

    Closely monitor patients to avoid undertreatment and overtreatment. Undertreatment may result in poor school performance due to impaired concentration and slowed mentation and in reduced adult height. Overtreatment may accelerate the bone age and result in premature epiphyseal closure and compromised adult stature.

    Treated children may manifest a period of catch-up growth, which may be adequate in some cases to normalize adult height. In children with severe or prolonged hypothyroidism, catch-up growth may not be adequate to normalize adult height.

    8.5 Geriatric Use

    Because of the increased prevalence of cardiovascular disease among the elderly, initiate SYNTHROID at less than the full replacement dose [see Warnings and Precautions (5.1) and Dosage and Administration (2.3)]. Atrial arrhythmias can occur in elderly patients. Atrial fibrillation is the most common of the arrhythmias observed with levothyroxine overtreatment in the elderly.

    Close
  • 10 OVERDOSAGE

    The signs and symptoms of overdosage are those of hyperthyroidism [see Warnings and Precautions (5) and Adverse Reactions (6)]. In addition, confusion and disorientation may occur. Cerebral embolism, shock, coma, and death have been reported. Seizures occurred in a 3-year-old child ingesting 3.6 mg of levothyroxine. Symptoms may not necessarily be evident or may not appear until several days after ingestion of levothyroxine sodium.

    Reduce the SYNTHROID dose or discontinue temporarily if signs or symptoms of overdosage occur. Initiate appropriate supportive treatment as dictated by the patient’s medical status.

    For current information on the management of poisoning or overdosage, contact the National Poison Control Center at 1-800-222-1222 or www.poison.org.

    Close
  • 11 DESCRIPTION

    SYNTHROID (levothyroxine sodium tablets, USP) contain synthetic crystalline L-3,3',5,5'-tetraiodothyronine sodium salt [levothyroxine (T4) sodium]. Synthetic T4 is chemically identical to that produced in the human thyroid gland. Levothyroxine (T4) sodium has an empirical formula of C15H10I4N NaO4• H2O, molecular weight of 798.86 (anhydrous), and structural formula as shown:

    description

    SYNTHROID tablets for oral administration are supplied in the following strengths: 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg. Each SYNTHROID tablet contains the inactive ingredients acacia, confectioner's sugar (contains corn starch), lactose monohydrate, magnesium stearate, povidone, and talc. Each tablet strength meets USP Dissolution Test 3. Table 6 provides a listing of the color additives by tablet strength:

    Table 6. SYNTHROID Tablets Color Additives
    Strength
    (mcg)
    Color additive(s)
    25 FD&C Yellow No. 6 Aluminum Lakea
    50 None
    75 FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake
    88 FD&C Blue No. 1 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lakea, D&C Yellow No. 10 Aluminum Lake
    100 D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lakea
    112 D&C Red No. 27 & 30 Aluminum Lake
    125 FD&C Yellow No. 6 Aluminum Lakea, FD&C Red No. 40 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake
    137 FD&C Blue No. 1 Aluminum Lake
    150 FD&C Blue No. 2 Aluminum Lake
    175 FD&C Blue No. 1 Aluminum Lake, D&C Red No. 27 & 30 Aluminum Lake
    200 FD&C Red No. 40 Aluminum Lake
    300 D&C Yellow No. 10 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lakea, FD&C Blue No. 1 Aluminum Lake
    1. Note – FD&C Yellow No. 6 is orange in color.
    Close
  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Thyroid hormones exert their physiologic actions through control of DNA transcription and protein synthesis. Triiodothyronine(T3) and L-thyroxine (T4) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins.

    The physiological actions of thyroid hormones are produced predominantly by T3, the majority of which (approximately 80%) is derived from T4 by deiodination in peripheral tissues.

    12.2 Pharmacodynamics

    Oral levothyroxine sodium is a synthetic T4 hormone that exerts the same physiologic effect as endogenous T4, thereby maintaining normal T4 levels when a deficiency is present.

    12.3 Pharmacokinetics

    Absorption

    Absorption of orally administered T4 from the gastrointestinal tract ranges from 40% to 80%. The majority of the SYNTHROID dose is absorbed from the jejunum and upper ileum. The relative bioavailability of SYNTHROID tablets, compared to an equal nominal dose of oral levothyroxine sodium solution, is approximately 93%. T4 absorption is increased by fasting, and decreased in malabsorption syndromes and by certain foods such as soybeans. Dietary fiber decreases bioavailability of T4. Absorption may also decrease with age. In addition, many drugs and foods affect T4 absorption [see Drug Interactions (7)].

    Distribution

    Circulating thyroid hormones are greater than 99% bound to plasma proteins, including thyroxine-binding globulin (TBG), thyroxine-binding prealbumin (TBPA), and albumin (TBA), whose capacities and affinities vary for each hormone. The higher affinity of both TBG and TBPA for T4 partially explains the higher serum levels, slower metabolic clearance, and longer half-life of T4 compared to T3. Protein-bound thyroid hormones exist in reverse equilibrium with small amounts of free hormone. Only unbound hormone is metabolically active. Many drugs and physiologic conditions affect the binding of thyroid hormones to serum proteins [see Drug Interactions (7)]. Thyroid hormones do not readily cross the placental barrier [see Use in Specific Populations (8.1)].

    Elimination

    Metabolism

    T4 is slowly eliminated (see Table 7). The major pathway of thyroid hormone metabolism is through sequential deiodination. Approximately 80% of circulating T3 is derived from peripheral T4 by monodeiodination. The liver is the major site of degradation for both T4 and T3, with T4 deiodination also occurring at a number of additional sites, including the kidney and other tissues. Approximately 80% of the daily dose of T4 is deiodinated to yield equal amounts of T3 and reverse T3 (rT3). T3 and rT3 are further deiodinated to diiodothyronine. Thyroid hormones are also metabolized via conjugation with glucuronides and sulfates and excreted directly into the bile and gut where they undergo enterohepatic recirculation.

    Excretion

    Thyroid hormones are primarily eliminated by the kidneys. A portion of the conjugated hormone reaches the colon unchanged and is eliminated in the feces. Approximately 20% of T4 is eliminated in the stool. Urinary excretion of T4 decreases with age.

    Table 7. Pharmacokinetic Parameters of Thyroid Hormones in Euthyroid Patients
    Hormone Ratio in Thyroglobulin Biologic Potency t1/2 (days) Protein Binding (%)a
    Levothyroxine (T4) 10 - 20 1 6-7b 99.96
    Liothyronine (T3) 1 4 ≤ 2 99.5
    1. Includes TBG, TBPA, and TBA
    2. 3 to 4 days in hyperthyroidism, 9 to 10 days in hypothyroidism
    Close
  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Standard animal studies have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility of levothyroxine.

    Close
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    SYNTHROID (levothyroxine sodium, USP) tablets are supplied as follows:

    Strength
    (mcg)
    Color/Shape Tablet Markings NDC# for
    bottles of 90
    NDC # for
    bottles of 100
    NDC # for
    bottles of 1000
    NDC # for unit dose
    cartons of 100
    25 Orange/Round “SYNTHROID” and “25” 0074-4341-90 0074-4341-13 0074-4341-19 --
    50 White/Round “SYNTHROID” and “50” 0074-4552-90 0074-4552-13 0074-4552-19 0074-4552-11
    75 Violet/Round “SYNTHROID” and “75” 0074-5182-90 0074-5182-13 0074-5182-19 0074-5182-11
    88 Olive/Round “SYNTHROID” and “88” 0074-6594-90 0074-6594-13 0074-6594-19 --
    100 Yellow/Round “SYNTHROID” and “100” 0074-6624-90 0074-6624-13 0074-6624-19 0074-6624-11
    112 Rose/Round “SYNTHROID” and “112” 0074-9296-90 -- 0074-9296-19 --
    125 Brown/Round “SYNTHROID” and “125” 0074-7068-90 0074-7068-13 0074-7068-19 0074-7068-11
    137 Turquoise/Round “SYNTHROID” and “137” 0074-3727-90 -- 0074-3727-19 --
    150 Blue/Round “SYNTHROID” and “150” 0074-7069-90 -- 0074-7069-19 0074-7069-11
    175 Lilac/Round “SYNTHROID” and “175” 0074-7070-90 0074-7070-13 0074-7070-19 --
    200 Pink/Round “SYNTHROID” and “200” 0074-7148-90 -- 0074-7148-19 0074-7148-11
    300 Green/Round “SYNTHROID” and “300” 0074-7149-90 -- 0074-7149-19 --

    Storage Conditions

    Store at 25°C (77°F); excursions permitted to 15° to 30° C (59° to 86° F)

    [see USP Controlled Room Temperature]. SYNTHROID tablets should be protected from light and moisture.

    Close
  • 17 PATIENT COUNSELING INFORMATION

    Inform the patient of the following information to aid in the safe and effective use of SYNTHROID:

    Dosing and Administration

    • Instruct patients to take SYNTHROID only as directed by their healthcare provider.
    • Instruct patients to take SYNTHROID as a single dose, preferably on an empty stomach, one-half to one hour before breakfast.
    • Inform patients that agents such as iron and calcium supplements and antacids can decrease the absorption of levothyroxine. Instruct patients not to take SYNTHROID tablets within 4 hours of these agents.
    • Instruct patients to notify their healthcare provider if they are pregnant or breastfeeding or are thinking of becoming pregnant while taking SYNTHROID.

    Important Information

    • Inform patients that it may take several weeks before they notice an improvement in symptoms.
    • Inform patients that the levothyroxine in SYNTHROID is intended to replace a hormone that is normally produced by the thyroid gland. Generally, replacement therapy is to be taken for life.
    • Inform patients that SYNTHROID should not be used as a primary or adjunctive therapy in a weight control program.
    • Instruct patients to notify their healthcare provider if they are taking any other medications, including prescription and over-the-counter preparations.
    • Instruct patients to notify their physician of any other medical conditions they may have, particularly heart disease, diabetes, clotting disorders, and adrenal or pituitary gland problems, as the dose of medications used to control these other conditions may need to be adjusted while they are taking SYNTHROID. If they have diabetes, instruct patients to monitor their blood and/or urinary glucose levels as directed by their physician and immediately report any changes to their physician. If patients are taking anticoagulants, their clotting status should be checked frequently.
    • Instruct patients to notify their physician or dentist that they are taking SYNTHROID prior to any surgery.

    Adverse Reactions

    • Instruct patients to notify their healthcare provider if they experience any of the following symptoms: rapid or irregular heartbeat, chest pain, shortness of breath, leg cramps, headache, nervousness, irritability, sleeplessness, tremors, change in appetite, weight gain or loss, vomiting, diarrhea, excessive sweating, heat intolerance, fever, changes in menstrual periods, hives or skin rash, or any other unusual medical event.
    • Inform patients that partial hair loss may occur rarely during the first few months of SYNTHROID therapy, but this is usually temporary.
    Close
  • SPL UNCLASSIFIED SECTION

    © 2017 AbbVie Inc.

    AbbVie Inc.

    North Chicago, IL 60064, U.S.A.

    03-A648 February 2017

    Close
  • PRINCIPAL DISPLAY PANEL

    NDC 0074–4552–11

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    50 mcg (0.05 mg)

    100 Tablets

    THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN

    Rx only abbvie

    synthroid 50mcg 100 ct hud

    NDC 0074–6624–11

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    100 mcg (0.1 mg)

    100 Tablets

    THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN

    Rx only abbvie

    synthroid 100 mcg 100ct-hud

    NDC 0074–7148–11

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    200 mcg (0.2 mg)

    100 Tablets

    THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN

    Rx only abbvie

    synthroid 200mcg 100 tablets- hud

    NDC 0074–3727–90

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    137 mcg (0.137 mg)

    90 Tablets

    Rx only abbvie

    137 mcg 90 ct

    NDC 0074–4341–19

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    25 mcg (0.025 mg)

    1000 Tablets

    Rx only abbvie

    25 mcg 1000ct

    NDC 0074–5182–19

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    75 mcg (0.075 mg)

    1000 Tablets

    Rx only abbvie

    75 mcg 1000ct

    NDC 0074–6594–90

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    88 mcg (0.088 mg)

    90 Tablets

    Rx only abbvie

    88 mcg 90 ct

    NDC 0074–7068–19

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    125 mcg (0.125 mg)

    1000 Tablets

    Rx only abbvie

    125 mcg 1000ct

    NDC 0074–7069–90

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    150 mcg (0.15 mg)

    90 Tablets

    Rx only abbvie

    150 mcg 90 ct

    NDC 0074–7070–19

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    175 mcg (0.175 mg)

    1000 Tablets

    Rx only abbvie

    175 mcg 1000 ct

    NDC 0074–7149–90

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    300 mcg (0.3 mg)

    90 Tablets

    Rx only abbvie

    300 mcg 90 ct

    NDC 0074–9296–19

    Synthroid®

    Levothyroxine Sodium Tablets, USP

    112 mcg (0.112 mg)

    1000 Tablets

    Rx only abbvie

    112 mcg 1000ct

    Close
  • INGREDIENTS AND APPEARANCE
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-7149
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 300 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color GREEN Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;300
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-7149-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    2 NDC:0074-7149-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-4341
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 25 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color ORANGE Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;25
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-4341-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 04/13/2012
    2 NDC:0074-4341-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-4341-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    4 NDC:0074-4341-72 2 in 1 CARTON 06/03/2016
    4 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-4552
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 50 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color WHITE Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;50
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-4552-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 05/18/2012
    2 NDC:0074-4552-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-4552-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    4 NDC:0074-4552-11 10 in 1 BOX, UNIT-DOSE 07/24/2002
    4 10 in 1 BLISTER PACK; Type 0: Not a Combination Product
    5 NDC:0074-4552-71 4 in 1 CARTON 07/24/2002
    5 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    6 NDC:0074-4552-72 2 in 1 CARTON 07/24/2002
    6 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-5182
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 75 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color PURPLE (Violet) Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;75
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-5182-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 04/25/2012
    2 NDC:0074-5182-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-5182-71 4 in 1 CARTON 07/24/2002
    3 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    4 NDC:0074-5182-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    5 NDC:0074-5182-11 10 in 1 BOX, UNIT-DOSE 07/24/2002
    5 10 in 1 BLISTER PACK; Type 0: Not a Combination Product
    6 NDC:0074-5182-72 2 in 1 CARTON 07/24/2002
    6 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-6624
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 100 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color YELLOW Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;100
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-6624-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 05/21/2012
    2 NDC:0074-6624-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-6624-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    4 NDC:0074-6624-11 10 in 1 BOX, UNIT-DOSE 07/24/2002
    4 10 in 1 BLISTER PACK; Type 0: Not a Combination Product
    5 NDC:0074-6624-71 4 in 1 CARTON 07/24/2002
    5 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    6 NDC:0074-6624-72 2 in 1 CARTON 07/24/2002
    6 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-6594
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 88 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color GREEN (Olive) Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;88
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-6594-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 05/02/2012
    2 NDC:0074-6594-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-6594-71 4 in 1 CARTON 07/24/2002
    3 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    4 NDC:0074-6594-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    5 NDC:0074-6594-72 2 in 1 CARTON 07/24/2002
    5 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-9296
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 112 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    D&C RED NO. 27 (UNII: 2LRS185U6K)  
    D&C RED NO. 30 (UNII: 2S42T2808B)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color RED (Rose) Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;112
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-9296-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 04/15/2011
    2 NDC:0074-9296-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-9296-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    4 NDC:0074-9296-71 4 in 1 CARTON 07/24/2002
    4 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    5 NDC:0074-9296-72 2 in 1 CARTON 07/24/2002
    5 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-7068
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 125 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color BROWN Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;125
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-7068-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 04/14/2012
    2 NDC:0074-7068-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-7068-71 4 in 1 CARTON 07/24/2002
    3 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    4 NDC:0074-7068-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    5 NDC:0074-7068-11 10 in 1 BOX, UNIT-DOSE 07/24/2002
    5 10 in 1 BLISTER PACK; Type 0: Not a Combination Product
    6 NDC:0074-7068-72 2 in 1 CARTON 07/24/2002
    6 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-3727
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 137 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color BLUE (Turquoise) Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;137
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-3727-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 04/15/2011
    2 NDC:0074-3727-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-3727-71 4 in 1 CARTON 07/24/2002
    3 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    4 NDC:0074-3727-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    5 NDC:0074-3727-72 2 in 1 CARTON 07/24/2002
    5 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-7069
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 150 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C BLUE NO. 2 (UNII: L06K8R7DQK)  
    SUCROSE (UNII: C151H8M554)  
    POVIDONES (UNII: FZ989GH94E)  
    Product Characteristics
    Color BLUE Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;150
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-7069-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    2 NDC:0074-7069-71 4 in 1 CARTON 07/24/2002
    2 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    3 NDC:0074-7069-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    4 NDC:0074-7069-11 10 in 1 BOX, UNIT-DOSE 07/24/2002
    4 10 in 1 BLISTER PACK; Type 0: Not a Combination Product
    5 NDC:0074-7069-72 2 in 1 CARTON 07/24/2002
    5 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-7070
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 175 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C BLUE NO. 1 (UNII: H3R47K3TBD)  
    D&C RED NO. 27 (UNII: 2LRS185U6K)  
    D&C RED NO. 30 (UNII: 2S42T2808B)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color PURPLE (Lilac) Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;175
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-7070-13 100 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002 03/06/2012
    2 NDC:0074-7070-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    3 NDC:0074-7070-71 4 in 1 CARTON 07/24/2002
    3 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    4 NDC:0074-7070-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 07/24/2002
    5 NDC:0074-7070-72 2 in 1 CARTON 07/24/2002
    5 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 07/24/2002
    SYNTHROID 
    levothyroxine sodium tablet
    Product Information
    Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:0074-7148
    Route of Administration ORAL
    Active Ingredient/Active Moiety
    Ingredient Name Basis of Strength Strength
    LEVOTHYROXINE SODIUM (UNII: 9J765S329G) (LEVOTHYROXINE - UNII:Q51BO43MG4) LEVOTHYROXINE SODIUM ANHYDROUS 200 ug
    Inactive Ingredients
    Ingredient Name Strength
    ACACIA (UNII: 5C5403N26O)  
    LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)  
    MAGNESIUM STEARATE (UNII: 70097M6I30)  
    TALC (UNII: 7SEV7J4R1U)  
    FD&C RED NO. 40 (UNII: WZB9127XOA)  
    POVIDONES (UNII: FZ989GH94E)  
    SUCROSE (UNII: C151H8M554)  
    Product Characteristics
    Color PINK Score 2 pieces
    Shape ROUND Size 7mm
    Flavor Imprint Code SYNTHROID;200
    Contains     
    Packaging
    # Item Code Package Description Marketing Start Date Marketing End Date
    1 NDC:0074-7148-90 90 in 1 BOTTLE; Type 0: Not a Combination Product 02/24/2002
    2 NDC:0074-7148-19 1000 in 1 BOTTLE; Type 0: Not a Combination Product 02/24/2002
    3 NDC:0074-7148-71 4 in 1 CARTON 02/24/2002
    3 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    4 NDC:0074-7148-11 10 in 1 BOX, UNIT-DOSE 02/24/2002
    4 10 in 1 BLISTER PACK; Type 0: Not a Combination Product
    5 NDC:0074-7148-72 2 in 1 CARTON 02/24/2002
    5 7 in 1 BLISTER PACK; Type 0: Not a Combination Product
    Marketing Information
    Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
    NDA NDA021402 02/24/2002
    Labeler - AbbVie Inc. (078458370)
    Close